Daniela Maria Cirillo

List of Publications by Year
in descending order

276	15,592	19657 61	23533 111
papers	citations	h-index	g-index

292	292	292	12722
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Towards tuberculosis elimination: an action framework for low-incidence countries. European Respiratory Journal, 2015, 45, 928-952.	6.7	608
2	Macrophage-dependent induction of theSalmonellapathogenicity island 2 type III secretion system and its role in intracellular survival. Molecular Microbiology, 1998, 30, 175-188.	2.5	563
3	Interferon-Â release assays for the diagnosis of latent Mycobacterium tuberculosis infection: a systematic review and meta-analysis. European Respiratory Journal, 2011, 37, 88-99.	6.7	490
4	LTBI: latent tuberculosis infection or lasting immune responses to M. tuberculosis? A TBNET consensus statement. European Respiratory Journal, 2009, 33, 956-973.	6.7	487
5	Xpert MTB/RIF Ultra for detection of Mycobacterium tuberculosis and rifampicin resistance: a prospective multicentre diagnostic accuracy study. Lancet Infectious Diseases, The, 2018, 18, 76-84.	9.1	474
6	Evolutionary history and global spread of the Mycobacterium tuberculosis Beijing lineage. Nature Genetics, 2015, 47, 242-249.	21.4	466
7	The New Xpert MTB/RIF Ultra: Improving Detection of Mycobacterium tuberculosis and Resistance to Rifampin in an Assay Suitable for Point-of-Care Testing. MBio, 2017, 8, .	4.1	431
8	Prediction of Susceptibility to First-Line Tuberculosis Drugs by DNA Sequencing. New England Journal of Medicine, 2018, 379, 1403-1415.	27.0	405
9	Mycobacterium tuberculosis lineage 4 comprises globally distributed and geographically restricted sublineages. Nature Genetics, 2016, 48, 1535-1543.	21.4	326
10	A standardised method for interpreting the association between mutations and phenotypic drug resistance inMycobacterium tuberculosis. European Respiratory Journal, 2017, 50, 1701354.	6.7	273
11	Clinical validation of Xpert MTB/RIF for the diagnosis of extrapulmonary tuberculosis. European Respiratory Journal, 2012, 40, 442-447.	6.7	271
12	PhyResSE: a Web Tool Delineating Mycobacterium tuberculosis Antibiotic Resistance and Lineage from Whole-Genome Sequencing Data. Journal of Clinical Microbiology, 2015, 53, 1908-1914.	3.9	257
13	Management of patients with multidrug-resistant/extensively drug-resistant tuberculosis in Europe: a TBNET consensus statement. European Respiratory Journal, 2014, 44, 23-63.	6.7	256
14	Whole genome sequencing of Mycobacterium tuberculosis: current standards and open issues. Nature Reviews Microbiology, 2019, 17, 533-545.	28.6	237
15	Dynamic antibody responses to the Mycobacterium tuberculosis proteome. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 14703-14708.	7.1	225
16	Rapid molecular TB diagnosis: evidence, policy making and global implementation of Xpert MTB/RIF. European Respiratory Journal, 2013, 42, 252-271.	6.7	211
17	Risk Assessment of Tuberculosis in Immunocompromised Patients. A TBNET Study. American Journal of Respiratory and Critical Care Medicine, 2014, 190, 1168-1176.	5.6	196
18	Emended description of Mycobacterium abscessus, Mycobacterium abscessus subsp. abscessus and Mycobacterium abscessus subsp. bolletii and designation of Mycobacterium abscessus subsp. massiliense comb. nov.. International Journal of Systematic and Evolutionary Microbiology, 2016, 66, 4471-4479.	1.7	190

#	Article	IF	Citations
19	European Union Standards for Tuberculosis Care. European Respiratory Journal, 2012, 39, 807-819.	6.7	188
20	Clinical and operational value of the extensively drug-resistant tuberculosis definition. European Respiratory Journal, 2007, 30, 623-626.	6.7	179
21	Correlates of tuberculosis risk: predictive biomarkers for progression to active tuberculosis. European Respiratory Journal, 2016, 48, 1751-1763.	6.7	165
22	Epidemiology and clinical management of XDR-TB: a systematic review by TBNET. European Respiratory Journal, 2009, 33, 871-881.	6.7	163
23	Population-based resistance of Mycobacterium tuberculosis isolates to pyrazinamide and fluoroquinolones: results from a multicountry surveillance project. Lancet Infectious Diseases, The, 2016, 16, 1185-1192.	9.1	151
24	Use of a T-cell interferon-Â release assay for the diagnosis of tuberculous pleurisy. European Respiratory Journal, 2007, 30, 1173-1179.	6.7	150
25	Tuberculosis elimination: theory and practice in Europe. European Respiratory Journal, 2014, 43, 1410-1420.	6.7	148
26	MTBseq: a comprehensive pipeline for whole genome sequence analysis of Mycobacterium tuberculosis complex isolates. PeerJ, 2018, 6, e5895.	2.0	148
27	Adaptation of Pseudomonas aeruginosa in Cystic Fibrosis Airways Influences Virulence of Staphylococcus aureus In Vitro and Murine Models of Co-Infection. PLoS ONE, 2014, 9, e89614.	2.5	138
28	Defining the Needs for Next Generation Assays for Tuberculosis. Journal of Infectious Diseases, 2015, 211, S29-S38.	4.0	133
29	Resistance to second-line injectables and treatment outcomes in multidrug-resistant and extensively drug-resistant tuberculosis cases. European Respiratory Journal, 2008, 31, 1155-1159.	6.7	131
30	Treatment outcome with a short multidrug-resistant tuberculosis regimen in nine African countries. International Journal of Tuberculosis and Lung Disease, 2018, 22, 17-25.	1.2	130
31	The new phylogeny of the genus Mycobacterium : The old and the news. Infection, Genetics and Evolution, 2017, 56, 19-25.	2.3	128
32	MDR/XDR-TB management of patients and contacts: Challenges facing the new decade. The 2020 clinical update by the Global Tuberculosis Network. International Journal of Infectious Diseases, 2020, 92, S15-S25.	3.3	126
33	Mycobacterium tuberculosis Pyrazinamide Resistance Determinants: a Multicenter Study. MBio, 2014, 5, e01819-14.	4.1	125
34	Clinical implications of molecular drug resistance testing for <I>Mycobacterium tuberculosis</I>: a TBNET/RESIST-TB consensus statement. International Journal of Tuberculosis and Lung Disease, 2016, 20, 24-42.	1.2	123
35	A cluster of multidrug-resistant Mycobacterium tuberculosis among patients arriving in Europe from the Horn of Africa: a molecular epidemiological study. Lancet Infectious Diseases, The, 2018, 18, 431-440.	9.1	121
36	First evaluation of QuantiFERON-TB Gold Plus performance in contact screening. European Respiratory Journal, 2016, 48, 1411-1419.	6.7	119

#	Article	IF	Citations
37	Genetic sequencing for surveillance of drug resistance in tuberculosis in highly endemic countries: a multi-country population-based surveillance study. Lancet Infectious Diseases, The, 2018, 18, 675-683.	9.1	119
38	The 2021 WHO catalogue of Mycobacterium tuberculosis complex mutations associated with drug resistance: a genotypic analysis. Lancet Microbe, The, 2022, 3, e265-e273.	7.3	114
39	Diagnostic Performance of the New Version (v2.0) of GenoType MTBDR sl Assay for Detection of Resistance to Fluoroquinolones and Second-Line Injectable Drugs: a Multicenter Study. Journal of Clinical Microbiology, 2015, 53, 2961-2969.	3.9	111
40	Use of a T-cell-based test for detection of tuberculosis infection among immunocompromised patients. European Respiratory Journal, 2006, 28, 31-34.	6.7	107
41	Antibiotic resistance prediction for Mycobacterium tuberculosis from genome sequence data with Mykrobe. Wellcome Open Research, 2019, 4, 191.	1.8	103
42	Multidrug-resistant and extensively drug-resistantMycobacterium tuberculosis: epidemiology and control. Expert Review of Anti-Infective Therapy, 2007, 5, 857-871.	4.4	101
43	First characterization of the CD4 and CD8 T-cell responses to QuantiFERON-TB Plus. Journal of Infection, 2016, 73, 588-597.	3.3	101
44	Challenges and perspectives in the diagnosis of extrapulmonary tuberculosis. Expert Review of Anti-Infective Therapy, 2014, 12, 633-647.	4.4	100
45	Use of Genotype MTBDR Assay for Molecular Detection of Rifampin and Isoniazid Resistance in Mycobacterium tuberculosis Clinical Strains Isolated in Italy. Journal of Clinical Microbiology, 2006, 44, 2485-2491.	3.9	98
46	Extensively Drug-resistant Tuberculosis, Italy and Germany. Emerging Infectious Diseases, 2007, 13, 780-782.	4.3	96
47	Whole genome sequencing of Mycobacterium tuberculosis for detection of drug resistance: a systematic review. Clinical Microbiology and Infection, 2017, 23, 61-68.	6.0	95
48	Analytical evaluation of QuantiFERON- Plus and QuantiFERON- Gold In-tube assays in subjects with or without tuberculosis. Tuberculosis, 2017, 106, 38-43.	1.9	89
49	Epidemic and pandemic viral infections: impact on tuberculosis and the lung. European Respiratory Journal, 2020, 56, 2001727.	6.7	89
50	Role of Disputed Mutations in the rpoB Gene in Interpretation of Automated Liquid MGIT Culture Results for Rifampin Susceptibility Testing of Mycobacterium tuberculosis. Journal of Clinical Microbiology, 2018, 56, .	3.9	88
51	Accuracy of Immunodiagnostic Tests for Active Tuberculosis Using Single and Combined Results: A Multicenter TBNET-Study. PLoS ONE, 2008, 3, e3417.	2.5	88
52	Revisiting susceptibility testing in MDR-TB by a standardized quantitative phenotypic assessment in a European multicentre study. Journal of Antimicrobial Chemotherapy, 2015, 70, 686-696.	3.0	87
53	First independent evaluation of QuantiFERON-TB Plus performance. European Respiratory Journal, 2016, 47, 1587-1590.	6.7	87
54	Collaborative Effort for a Centralized Worldwide Tuberculosis Relational Sequencing Data Platform: Figure 1.. Clinical Infectious Diseases, 2015, 61, S141-S146.	5.8	78

#	Article	IF	Citations
55	Integrating standardized whole genome sequence analysis with a global Mycobacterium tuberculosis antibiotic resistance knowledgebase. Scientific Reports, 2018, 8, 15382.	3.3	75
56	TB and MDR/XDR-TB in European Union and European Economic Area countries: managed or mismanaged?. European Respiratory Journal, 2012, 39, 619-625.	6.7	74
57	Prevalence and genetic profiles of isoniazid resistance in tuberculosis patients: A multicountry analysis of cross-sectional data. PLoS Medicine, 2020, 17, e1003008.	8.4	74
58	Genotype MTBDR plus : a Further Step toward Rapid Identification of Drug-Resistant Mycobacterium tuberculosis. Journal of Clinical Microbiology, 2008, 46, 393-394.	3.9	73
59	Can we predict tuberculosis cure? What tools are available?. European Respiratory Journal, 2018, 52, 1801089.	6.7	73
60	Genome-Wide Discovery of Small RNAs in Mycobacterium tuberculosis. PLoS ONE, 2012, 7, e51950.	2.5	70
61	miRNA Signatures in Sera of Patients with Active Pulmonary Tuberculosis. PLoS ONE, 2013, 8, e80149.	2.5	70
62	Delamanid susceptibility testing ofMycobacterium tuberculosisusing the resazurin microtitre assay and the BACTECâ„¢ MGITâ„¢ 960 system. Journal of Antimicrobial Chemotherapy, 2016, 71, 1532-1539.	3.0	68
63	Fluoroquinolones: are they essential to treat multidrug-resistant tuberculosis?. European Respiratory Journal, 2008, 31, 904-905.	6.7	67
64	Totally Drug-Resistant and Extremely Drug-Resistant Tuberculosis: The Same Disease?. Clinical Infectious Diseases, 2012, 54, 1379-1380.	5.8	67
65	Alteration of human macrophages microRNA expression profile upon infection with Mycobacterium tuberculosis. International Journal of Mycobacteriology, 2013, 2, 128-134.	0.6	65
66	Mycobacterium abscessusin patients with cystic fibrosis: low impact of inter-human transmission in Italy. European Respiratory Journal, 2017, 50, 1602525.	6.7	63
67	Blood neurofilament light chain and total tau levels at admission predict death in COVID-19 patients. Journal of Neurology, 2021, 268, 4436-4442.	3.6	63
68	Drug resistance mechanisms and drug susceptibility testing for tuberculosis. Respirology, 2018, 23, 1098-1113.	2.3	62
69	Validating a 14-Drug Microtiter Plate Containing Bedaquiline and Delamanid for Large-Scale Research Susceptibility Testing of Mycobacterium tuberculosis. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	62
70	Early tuberculosis treatment monitoring by XpertÂ® MTB/RIF: Figure 1â€“. European Respiratory Journal, 2012, 39, 1269-1271.	6.7	61
71	Genome-based taxonomic revision detects a number of synonymous taxa in the genus Mycobacterium. Infection, Genetics and Evolution, 2019, 75, 103983.	2.3	61
72	Integrating Pharmacokinetics and Pharmacodynamics in Operational Research to End Tuberculosis. Clinical Infectious Diseases, 2020, 70, 1774-1780.	5.8	59

#	Article	IF	Citations
73	Population structure, biogeography and transmissibility of Mycobacterium tuberculosis. Nature Communications, 2021, 12, 6099.	12.8	59
74	Hepcidin levels predict <scp>Covidâ€19</scp> severity and mortality in a cohort of hospitalized Italian patients. American Journal of Hematology, 2021, 96, E32-E35.	4.1	58
75	Deep amplicon sequencing for culture-free prediction of susceptibility or resistance to 13 anti-tuberculous drugs. European Respiratory Journal, 2021, 57, 2002338.	6.7	58
76	Application of Targeted Next-Generation Sequencing Assay on a Portable Sequencing Platform for Culture-Free Detection of Drug-Resistant Tuberculosis from Clinical Samples. Journal of Clinical Microbiology, 2020, 58, .	3.9	57
77	Same meat, different gravy: ignore the new names of mycobacteria. European Respiratory Journal, 2019, 54, 1900795.	6.7	54
78	Prevalence and molecular characteristics of Staphylococcus aureus, including methicillin resistant strains, isolated from bulk can milk and raw milk products in pastoral communities of South-West Uganda. BMC Infectious Diseases, 2017, 17, 422.	2.9	53
79	TB and M/XDR-TB infection control in European TB reference centres: the Achilles' heel?. European Respiratory Journal, 2011, 38, 1221-1223.	6.7	52
80	The roles of microRNAs on tuberculosis infection: Meaning or myth?. Tuberculosis, 2013, 93, 596-605.	1.9	52
81	ERS/ECDC Statement: European Union standards for tuberculosis care, 2017Âupdate. European Respiratory Journal, 2018, 51, 1702678.	6.7	50
82	Antimicrobial susceptibility testing of Mycobacterium tuberculosis complex isolates â€“ the EUCAST broth microdilution reference method for MIC determination. Clinical Microbiology and Infection, 2020, 26, 1488-1492.	6.0	49
83	Acquisition of Cross-Resistance to Bedaquiline and Clofazimine following Treatment for Tuberculosis in Pakistan. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.2	47
84	Characterization of Genomic Variants Associated with Resistance to Bedaquiline and Delamanid in Naive Mycobacterium tuberculosis Clinical Strains. Journal of Clinical Microbiology, 2020, 58, .	3.9	46
85	Clostridium difficile PCR Ribotype 018, a Successful Epidemic Genotype. Journal of Clinical Microbiology, 2015, 53, 2575-2580.	3.9	44
86	A Genome-Wide Identification Analysis of Small Regulatory RNAs in Mycobacterium tuberculosis by RNA-Seq and Conservation Analysis. PLoS ONE, 2012, 7, e32723.	2.5	43
87	Xpert MTB/XDR: a 10-Color Reflex Assay Suitable for Point-of-Care Settings To Detect Isoniazid, Fluoroquinolone, and Second-Line-Injectable-Drug Resistance Directly from Mycobacterium tuberculosis-Positive Sputum. Journal of Clinical Microbiology, 2021, 59, .	3.9	43
88	Molecular diversity of Mycobacterium tuberculosis isolates from patients with pulmonary tuberculosis in Mozambique. BMC Microbiology, 2010, 10, 195.	3.3	42
89	Drug Resistance in Mycobacterium tuberculosis. Chest, 2015, 147, 1135-1143.	0.8	42
90	A Multilaboratory, Multicountry Study To Determine MIC Quality Control Ranges for Phenotypic Drug Susceptibility Testing of Selected First-Line Antituberculosis Drugs, Second-Line Injectables, Fluoroquinolones, Clofazimine, and Linezolid. Journal of Clinical Microbiology, 2016, 54, 2963-2968.	3.9	42

#	Article	IF	Citations
91	Towards standardisation: comparison of five whole genome sequencing (WGS) analysis pipelines for detection of epidemiologically linked tuberculosis cases. Eurosurveillance, 2019, 24, .	7.0	42
92	Lab-on-Chip-Based Platform for Fast Molecular Diagnosis of Multidrug-Resistant Tuberculosis. Journal of Clinical Microbiology, 2015, 53, 3876-3880.	3.9	41
93	The use of digital PCR to improve the application of quantitative molecular diagnostic methods for tuberculosis. BMC Infectious Diseases, 2016, 16, 366.	2.9	41
94	Celebrating World Tuberculosis Day at the time of COVID-19. European Respiratory Journal, 2020, 55, 2000650.	6.7	41
95	CXCL10 levels at hospital admission predict COVID-19 outcome: hierarchical assessment of 53 putative inflammatory biomarkers in an observational study. Molecular Medicine, 2021, 27, 129.	4.4	41
96	Staphylococcus aureus Impacts Pseudomonas aeruginosa Chronic Respiratory Disease in Murine Models. Journal of Infectious Diseases, 2018, 217, 933-942.	4.0	39
97	A Multilaboratory, Multicountry Study To Determine Bedaquiline MIC Quality Control Ranges for Phenotypic Drug Susceptibility Testing. Journal of Clinical Microbiology, 2016, 54, 2956-2962.	3.9	38
98	DeepAMR for predicting co-occurrent resistance of Mycobacterium tuberculosis. Bioinformatics, 2019, 35, 3240-3249.	4.1	38
99	GenoType MTBDRslperformance on clinical samples with diverse genetic background. European Respiratory Journal, 2012, 40, 690-698.	6.7	37
100	The prospects for the <scp>SARS</scp> â€CoVâ€2 pandemic in Africa. EMBO Molecular Medicine, 2020, 12, e12488.	6.9	37
101	Factors Contributing to Epidemic MRSA Clones Replacement in a Hospital Setting. PLoS ONE, 2012, 7, e43153.	2.5	36
102	Target Product Profile of a Molecular Drug-Susceptibility Test for Use in Microscopy Centers. Journal of Infectious Diseases, 2015, 211, S39-S49.	4.0	36
103	Impact of the COVID-19 pandemic on tuberculosis laboratory services in Europe. European Respiratory Journal, 2021, 57, 2003890.	6.7	36
104	Extensively Drug-Resistant Tuberculosis Is Worse than Multidrug-Resistant Tuberculosis: Different Methodology and Settings, Same Results. Clinical Infectious Diseases, 2008, 46, 958-959.	5.8	35
105	Whole genome sequencing of Mycobacterium tuberculosis. European Respiratory Journal, 2018, 52, 1801163.	6.7	35
106	Tests for tuberculosis infection: landscape analysis. European Respiratory Journal, 2021, 58, 2100167.	6.7	35
107	Role of Epistasis in Amikacin, Kanamycin, Bedaquiline, and Clofazimine Resistance in Mycobacterium tuberculosis Complex. Antimicrobial Agents and Chemotherapy, 2021, 65, e0116421.	3.2	35
108	Tuberculosis: lights and shadows in the current diagnostic landscape. New Microbiologica, 2013, 36, 111-20.	0.1	35

#	Article	IF	Citations
109	Comparison of core-genome MLST, coreSNP and PFGE methods for Klebsiella pneumoniae cluster analysis. Microbial Genomics, 2020, 6, .	2.0	34
110	Ancient and recent differences in the intrinsic susceptibility of Mycobacterium tuberculosis complex to pretomanid. Journal of Antimicrobial Chemotherapy, 2022, 77, 1685-1693.	3.0	34
111	Control of infectious mortality due to carbapenemase-producing Klebsiella pneumoniae in hematopoietic stem cell transplantation. Bone Marrow Transplantation, 2017, 52, 114-119.	2.4	33
112	Integration of Published Information Into a Resistance-Associated Mutation Database for Mycobacterium tuberculosis. Journal of Infectious Diseases, 2015, 211, S50-S57.	4.0	32
113	Isoniazid Resistance in Mycobacterium tuberculosis Is a Heterogeneous Phenotype Composed of Overlapping MIC Distributions with Different Underlying Resistance Mechanisms. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.2	32
114	mig-14 Is a Horizontally Acquired, Host-Induced Gene Required for Salmonella enterica Lethal Infection in the Murine Model of Typhoid Fever. Infection and Immunity, 2000, 68, 7126-7131.	2.2	31
115	Is Real-Time PCR Better than Conventional PCR for Mycobacterium tuberculosis Complex Detection in Clinical Samples?. Journal of Clinical Microbiology, 2012, 50, 2810-2813.	3.9	29
116	New Role for Human Î±-Defensin 5 in the Fight against Hypervirulent Clostridium difficile Strains. Infection and Immunity, 2015, 83, 986-995.	2.2	29
117	Recommendations for the diagnosis of pediatric tuberculosis. European Journal of Clinical Microbiology and Infectious Diseases, 2016, 35, 1-18.	2.9	29
118	Countrywide implementation of whole genome sequencing: an opportunity to improve tuberculosis management, surveillance and contact tracing in low incidence countries. European Respiratory Journal, 2018, 51, 1800387.	6.7	29
119	Alarming levels of multidrug-resistant tuberculosis in Ukraine: results from the first national survey. International Journal of Tuberculosis and Lung Disease, 2018, 22, 197-205.	1.2	29
120	Validation of Bedaquiline Phenotypic Drug Susceptibility Testing Methods and Breakpoints: a Multilaboratory, Multicountry Study. Journal of Clinical Microbiology, 2020, 58, .	3.9	29
121	Evolution of Phenotypic and Molecular Drug Susceptibility Testing. Advances in Experimental Medicine and Biology, 2017, 1019, 221-246.	1.6	28
122	Culture and Next-generation sequencing-based drug susceptibility testing unveil high levels of drug-resistant-TB in Djibouti: results from the first national survey. Scientific Reports, 2017, 7, 17672.	3.3	28
123	Molecular epidemiology of Panton-Valentine Leukocidin-positive community-acquired methicillin resistant Staphylococcus aureus isolates in pastoral communities of rural south western Uganda. BMC Infectious Diseases, 2017, 17, 24.	2.9	27
124	An evaluation framework for new tests that predict progression from tuberculosis infection to clinical disease. European Respiratory Journal, 2018, 52, 1800946.	6.7	27
125	Use of a Whole Genome Sequencing-based approach for Mycobacterium tuberculosis surveillance in Europe in 2017â€“2019: an ECDC pilot study. European Respiratory Journal, 2021, 57, 2002272.	6.7	27
126	From latent to patent: rethinking prediction of tuberculosis. Lancet Respiratory Medicine,the, 2017, 5, 243-244.	10.7	26

#	Article	IF	Citations
127	Tools to implement the World Health Organization End TB Strategy: Addressing common challenges in high and low endemic countries. International Journal of Infectious Diseases, 2020, 92, S60-S68.	3.3	26
128	Outcomes of a nine-month regimen for rifampicin-resistant tuberculosis up to 24 months after treatment completion in nine African countries. EClinicalMedicine, 2020, 20, 100268.	7.1	26
129	Mycobacterium persicum sp. nov., a novel species closely related to Mycobacterium kansasii and Mycobacterium gastri. International Journal of Systematic and Evolutionary Microbiology, 2017, 67, 1766-1770.	1.7	26
130	Tuberculosis Treatment Monitoring and Outcome Measures: New Interest and New Strategies. Clinical Microbiology Reviews, 2022, 35, e0022721.	13.6	26
131	Is multidrug-resistant tuberculosis on the rise in Mozambique? Results of a national drug resistance survey. European Respiratory Journal, 2011, 38, 222-224.	6.7	25
132	EUSeqMyTB to set standards and build capacity for whole genome sequencing for tuberculosis in the EU. Lancet Infectious Diseases, The, 2018, 18, 377.	9.1	25
133	GenomegaMap: Within-Species Genome-Wide dN/dS Estimation from over 10,000 Genomes. Molecular Biology and Evolution, 2020, 37, 2450-2460.	8.9	25
134	Screening for active and latent tuberculosis among asylum seekers in Italy: A retrospective cohort analysis. Travel Medicine and Infectious Disease, 2019, 27, 39-45.	3.0	22
135	Molecular detection of rifampin and isoniazid resistance to guide chronic TB patient management in Burkina Faso. BMC Infectious Diseases, 2009, 9, 142.	2.9	21
136	Children under 5â€…years are at risk for tuberculosis after occasional contact with highly contagious patients: outbreak from a smear-positive healthcare worker. European Respiratory Journal, 2017, 50, 1701414.	6.7	21
137	Evaluation of a novel line probe assay to detect resistance to pyrazinamide, a key drug used for tuberculosis treatment. Clinical Microbiology and Infection, 2018, 24, 60-64.	6.0	21
138	Mycobacterium abscessus, a taxonomic puzzle. International Journal of Systematic and Evolutionary Microbiology, 2018, 68, 467-469.	1.7	21
139	Automated detection of bacterial growth on 96-well plates for high-throughput drug susceptibility testing of Mycobacterium tuberculosis. Microbiology (United Kingdom), 2018, 164, 1522-1530.	1.8	21
140	Mycobacterium tuberculosis Beijing Genotype Is Associated with HIV Infection in Mozambique. PLoS ONE, 2013, 8, e71999.	2.5	21
141	First Report of Hypervirulent Strains Polymerase Chain Reaction Ribotypes 027 and 078 Causing SevereClostridium difficileInfection in Italy. Clinical Infectious Diseases, 2010, 50, 126-127.	5.8	20
142	Drug-resistant tuberculosis among foreign-born persons in Italy: Table 1â€“. European Respiratory Journal, 2012, 40, 497-500.	6.7	20
143	Utility of propidium monoazide viability assay as a biomarker for a tuberculosis disease. Tuberculosis, 2015, 95, 179-185.	1.9	20
144	Xpert MTB/RIF assay for diagnosis of pulmonary tuberculosis in children: A prospective, multi-centre evaluation. Journal of Infection, 2015, 70, 392-399.	3.3	20

#	Article	IF	Citations
145	Improved Detection of Tuberculosis and Multidrug-Resistant Tuberculosis among Tibetan Refugees, India. Emerging Infectious Diseases, 2016, 22, 463-468.	4.3	20
146	Emergence of two novel sequence types (3366 and 3367) NDM-1- and OXA-48-co-producing K. pneumoniae in Italy. European Journal of Clinical Microbiology and Infectious Diseases, 2019, 38, 1687-1691.	2.9	20
147	Whole Genome Sequencing Results Associated with Minimum Inhibitory Concentrations of 14 Anti-Tuberculosis Drugs among Rifampicin-Resistant Isolates of Mycobacterium Tuberculosis from Iran. Journal of Clinical Medicine, 2020, 9, 465.	2.4	20
148	High Prevalence of Shared International Type 53 among Mycobacterium tuberculosis Complex Strains in Retreated Patients from CÃ´te dâ€™Ivoire. PLoS ONE, 2012, 7, e45363.	2.5	20
149	Tuberculosis in Europe: a problem of drug resistance or much more?. Expert Review of Respiratory Medicine, 2010, 4, 189-200.	2.5	19
150	Tuberculosis in Kindergarten and Primary School, Italy, 2008â€“2009. Emerging Infectious Diseases, 2011, 17, 514-516.	4.3	19
151	Use of Commercial Interferon-Î³ Assays in Immunocompromised Patients for Tuberculosis Diagnosis. American Journal of Respiratory and Critical Care Medicine, 2006, 173, 130-130.	5.6	18
152	MIRU-VNTR Genotyping of Mycobacterium tuberculosis Strains Using QIAxcel Technology: A Multicentre Evaluation Study. PLoS ONE, 2016, 11, e0149435.	2.5	18
153	How To Optimally Combine Genotypic and Phenotypic Drug Susceptibility Testing Methods for Pyrazinamide. Antimicrobial Agents and Chemotherapy, 2020, 64, .	3.2	18
154	Severe community-onset infections in healthy individuals caused by community-acquired MRSA in an Italian teaching hospital, 2006â€“2008. Journal of Hospital Infection, 2009, 72, 271-273.	2.9	17
155	Survey of tuberculosis drug resistance among Tibetan refugees in India. International Journal of Tuberculosis and Lung Disease, 2014, 18, 655-662.	1.2	17
156	Epidemic MRSA clone ST22-IV is more resistant to multiple host- and environment-related stresses compared with ST228-I. Journal of Antimicrobial Chemotherapy, 2015, 70, 757-765.	3.0	17
157	Whole-Genome Sequencing of Drug-Resistant Mycobacterium tuberculosis Strains, Tunisia, 2012â€“2016. Emerging Infectious Diseases, 2019, 25, 538-546.	4.3	17
158	Preliminary observations on IGRA testing for TB infection in patients with severe COVID-19 eligible for immunosuppressive therapy. Respiratory Medicine, 2020, 175, 106204.	2.9	17
159	Emapalumab treatment in an ADA-SCID patient with refractory hemophagocytic lymphohistiocytosis-related graft failure and disseminated bacillus Calmette-GuÃ©rin infection. Haematologica, 2021, 106, 641-646.	3.5	17
160	Mycobacterium alsense sp. nov., a scotochromogenic slow grower isolated from clinical respiratory specimens. International Journal of Systematic and Evolutionary Microbiology, 2016, 66, 450-456.	1.7	17
161	Chronic infection by nontypeable Haemophilus influenzae fuels airway inflammation. ERJ Open Research, 2021, 7, 00614-2020.	2.6	17
162	Managing an extensively drug-resistant tuberculosis outbreak: the public health face of the medal. European Respiratory Journal, 2015, 45, 292-294.	6.7	16

#	Article	IF	Citations
163	Singleâ€center outbreak of Pneumocystis jirovecii pneumonia in heart transplant recipients. Transplant Infectious Disease, 2018, 20, e12880.	1.7	16
164	Trend in rifampicin-, multidrug- and extensively drug-resistant tuberculosis in Italy, 2009â€“2016. European Respiratory Journal, 2018, 52, 1800070.	6.7	16
165	Hospital outbreak due to Clostridium difficile ribotype 018 (RT018) in Southern Germany. International Journal of Medical Microbiology, 2019, 309, 189-193.	3.6	16
166	Tbnet â€" Collaborative research on tuberculosis in Europe. European Journal of Microbiology and Immunology, 2012, 2, 264-274.	2.8	15
167	Towards tackling tuberculosis in vulnerable groups in the European Union: the E-DETECT TB consortium. European Respiratory Journal, 2018, 51, 1702604.	6.7	15
168	Drug-Resistant Tuberculosis, Lebanon, 2016 â€“ 2017. Emerging Infectious Diseases, 2019, 25, 564-568.	4.3	15
169	Detection of NDM-1/5 and OXA-48 co-producing extensively drug-resistant hypervirulent Klebsiella pneumoniae in Northern Italy. Journal of Global Antimicrobial Resistance, 2022, 28, 146-150.	2.2	15
170	Longitudinal analysis of T cell receptor repertoires reveals shared patterns of antigen-specific response to SARS-CoV-2 infection. JCI Insight, 2022, 7, .	5.0	15
171	Updating the approaches to define susceptibility and resistance to anti-tuberculosis agents: implications for diagnosis and treatment. European Respiratory Journal, 2022, 59, 2200166.	6.7	15
172	Rifapentine access in Europe: growing concerns over key tuberculosis treatment component. European Respiratory Journal, 2022, 59, 2200388.	6.7	15
173	Comparison of an In-house and a Commercial RD1-based ELISPOT-IFN-Â Assay for the Diagnosis of Mycobacterium tuberculosis Infection. Clinical Medicine and Research, 2006, 4, 266-272.	0.8	14
174	Extensively Drug-Resistant Tuberculosis, Burkina Faso. Emerging Infectious Diseases, 2010, 16, 840-842.	4.3	14
175	Failing a re-treatment regimen does not predict MDR/XDR tuberculosis: is "blind" treatment dangerous?. European Respiratory Journal, 2011, 37, 1283-1285.	6.7	14
176	A New Model of Chronic Mycobacterium abscessus Lung Infection in Immunocompetent Mice. International Journal of Molecular Sciences, 2020, 21, 6590.	4.1	14
177	What is the role of the EUCAST reference method for MIC testing of the Mycobacterium tuberculosis complex?. Clinical Microbiology and Infection, 2020, 26, 1453-1455.	6.0	14
178	Whole genome sequencing of multidrug-resistant Mycobacterium tuberculosis isolates collected in the Czech Republic, 2005â€“2020. Scientific Reports, 2022, 12, 7149.	3.3	14
179	Genotypic and phenotypic relatedness of Pseudomonas aeruginosa isolates among the major cystic fibrosis patient cohort in Italy. BMC Microbiology, 2016, 16, 142.	3.3	13
180	Aiming for zero tuberculosis transmission in low-burden countries. Lancet Respiratory Medicine,the, 2017, 5, 846-848.	10.7	13

#	Article	IF	Citations
181	Mycobacterium decipiens sp. nov., a new species closely related to the Mycobacterium tuberculosis complex. International Journal of Systematic and Evolutionary Microbiology, 2018, 68, 3557-3562.	1.7	13
182	First Evaluation after Implementation of a Quality Control System for the Second Line Drug Susceptibility Testing of Mycobacterium tuberculosis Joint Efforts in Low and High Incidence Countries. PLoS ONE, 2013, 8, e76765.	2.5	13
183	Molecular typing of Mycobacterium Abscessus isolated from cystic fibrosis patients. International Journal of Mycobacteriology, 2017, 6, 138.	0.6	13
184	Pseudo-outbreak of Mycobacterium gordonae in a teaching hospital: importance of strictly following decontamination procedures and emerging issues concerning sterilization. New Microbiologica, 2016, 39, 25-34.	0.1	13
185	An outbreak caused by multidrug-resistant OXA-58-positive Acinetobacter baumannii in an intensive care unit in Italy. Journal of Hospital Infection, 2008, 68, 97-99.	2.9	12
186	Fatal vancomycin- and linezolid-resistant Enterococcus faecium sepsis in a child undergoing allogeneic haematopoietic stem cell transplantation for beta-thalassaemia major. Journal of Medical Microbiology, 2010, 59, 839-842.	1.8	12
187	Molecular Epidemiology and Genotyping ofMycobacterium tuberculosisIsolated in Baghdad. BioMed Research International, 2014, 2014, 1-15.	1.9	12
188	Tuberculosis in migrants from 106 countries to Italy, 2008â€“2014. European Respiratory Journal, 2016, 47, 1273-1276.	6.7	12
189	App-based symptoms screening with Xpert MTB/RIF Ultra assay used for active tuberculosis detection in migrants at point of arrivals in Italy: The E-DETECT TB intervention analysis. PLoS ONE, 2019, 14, e0218039.	2.5	12
190	Advantages and Challenges of Tailored Regimens for Drug-Resistant Tuberculosis: A StopTB Italia Look into the Future . Infection and Drug Resistance, 2020, Volume 13, 2795-2800.	2.7	12
191	Screening of inmates transferred to Spain reveals a Peruvian prison as a reservoir of persistent Mycobacterium tuberculosis MDR strains and mixed infections. Scientific Reports, 2020, 10, 2704.	3.3	12
192	Limited Capability for Testing Mycobacterium tuberculosis for Susceptibility to New Drugs. Emerging Infectious Diseases, 2021, 27, 985-987.	4.3	12
193	Combined Host- and Pathogen-Directed Therapy for the Control of Mycobacterium abscessus Infection. Microbiology Spectrum, 2022, 10, e0254621.	3.0	12
194	Moving towards tuberculosis elimination: a call for action from Italy and a possible model for other low tuberculosis incidence countries. European Respiratory Journal, 2017, 49, 1602242.	6.7	11
195	Is sequencing better than phenotypic tests for the detection of pyrazinamide resistance?. International Journal of Tuberculosis and Lung Disease, 2018, 22, 661-666.	1.2	11
196	Precision medicine and public health interventions: tuberculosis as a model?. Lancet Public Health, The, 2019, 4, e374.	10.0	11
197	QIAreach QuantiFERON-TB for the diagnosis of Mycobacterium tuberculosis infection. European Respiratory Journal, 2022, 59, 2102563.	6.7	11
198	Are mRNA based transcriptomic signatures ready for diagnosing tuberculosis in the clinic? - A review of evidence and the technological landscape. EBioMedicine, 2022, 82, 104174.	6.1	11

#	Article	IF	Citations
199	Proficiency testing of first- and second-line anti-tuberculosis drugs in Italy: Figure 1â€“. European Respiratory Journal, 2012, 39, 1263-1266.	6.7	10
200	Preliminary data on precision of QuantiFERON-TB Plus performance. European Respiratory Journal, 2016, 48, 955-956.	6.7	10
201	Guidance for Studies Evaluating the Accuracy of Rapid Tuberculosis Drug-Susceptibility Tests. Journal of Infectious Diseases, 2019, 220, S126-S135.	4.0	10
202	Building the Framework for Standardized Clinical Laboratory Reporting of Next-generation Sequencing Data for Resistance-associated Mutations in Mycobacterium tuberculosis Complex. Clinical Infectious Diseases, 2019, 69, 1631-1633.	5.8	10
203	Availability of anti-tuberculosis drugs in Europe: Table 1â€“. European Respiratory Journal, 2012, 40, 500-503.	6.7	9
204	An innovative silicon-chip for sensitive real time PCR improvement in pathogen detection. Analyst, The, 2019, 144, 2353-2358.	3.5	9
205	The Tuberculosis Network European Trials group (TBnet) ERS Clinical Research Collaboration: addressing drug-resistant tuberculosis through European cooperation. European Respiratory Journal, 2019, 53, 1802089.	6.7	9
206	Multicentre testing of the EUCAST broth microdilution reference method for MIC determination on Mycobacterium tuberculosis. Clinical Microbiology and Infection, 2021, 27, 288.e1-288.e4.	6.0	9
207	Framework for the evaluation of new tests for tuberculosis infection. European Respiratory Journal, 2021, 58, 2004078.	6.7	9
208	Mycobacterium angelicum sp. nov., a non-chromogenic, slow-growing species isolated from fish and related to Mycobacterium szulgai. International Journal of Systematic and Evolutionary Microbiology, 2015, 65, 4724-4729.	1.7	9
209	Chromogranin A plasma levels predict mortality in COVID-19. PLoS ONE, 2022, 17, e0267235.	2.5	9
210	Multidrug-resistant tuberculosis in cÃ´te d'ivoire from 1995 to 2016: Results of national surveys. European Journal of Microbiology and Immunology, 2018, 8, 91-94.	2.8	8
211	Isolation of the first New Delhi metallo-ÃŸ-lactamase-1 (NDM-1)-producing and colistin-resistant Klebsiella pneumoniae sequence type ST15 from a digestive carrier in Albania, May 2018. Journal of Global Antimicrobial Resistance, 2019, 17, 142-144.	2.2	8
212	Characteristics and Clinical Implications of Carbapenemase-Producing Klebsiella pneumoniae Colonization and Infection, Italy. Emerging Infectious Diseases, 2021, 27, 1416-1426.	4.3	8
213	Genomic analysis of cardiac surgery-associated Mycobacterium chimaera infections in Italy. PLoS ONE, 2020, 15, e0239273.	2.5	8
214	In vivo microevolution of Mycobacterium tuberculosis and transient emergence of atpE_Ala63Pro mutation during treatment in a pre-XDR TB patient. European Respiratory Journal, 2022, 59, 2102102.	6.7	8
215	Mycobacterium tuberculosisComplex Drug Resistance in Italy. Emerging Infectious Diseases, 2004, 10, 752-753.	4.3	7
216	Exportation of MDR TB to Europe from Setting with Actively Transmitted Persistent Strains in Peru. Emerging Infectious Diseases, 2019, 25, 596-598.	4.3	7

#	Article	IF	Citations
217	The neglected role of Faith-based Organizations in prevention and control of COVID-19 in Africa. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2020, 114, 784-786.	1.8	7
218	A Multimethod, Multicountry Evaluation of Breakpoints for Bedaquiline Resistance Determination. Antimicrobial Agents and Chemotherapy, 2020, 64, .	3.2	7
219	Integrative transnational analysis to dissect tuberculosis transmission events along the migratory route from Africa to Europe. Journal of Travel Medicine, 2021, 28, .	3.0	7
220	Assessment of the GenoType MTBDRsl VER 2.0 compared to the phenotypic drug susceptibility testing and whole genome sequencing for the rapid detection of resistance to fluoroquinolone and second-line injectable drugs among rifampicin-resistant Mycobacterium tuberculosis isolates. Archives of Microbiology, 2021, 203, 3989-3996.	2.2	7
221	SARS-CoV-2 Antibody Rapid Tests: Valuable Epidemiological Tools in Challenging Settings. Microbiology Spectrum, 2021, 9, e0025021.	3.0	7
222	Whole genome sequencing in Mycobacterium tuberculosis. Annals of Translational Medicine, 2019, 7, S197-S197.	1.7	7
223	Consensus Not Yet Reached on Key Drugs for Extensively Drugâ€Resistant Tuberculosis Treatment. Clinical Infectious Diseases, 2009, 49, 315-316.	5.8	6
224	Universal health coverage and social support in Senegal: a comprehensive approach against tuberculosis. European Respiratory Journal, 2015, 46, 869-871.	6.7	6
225	Implementation of a Consensus Set of Hypervariable Mycobacterial Interspersed Repetitive-Unitâ€“Variable-Number Tandem-Repeat Loci in Mycobacterium tuberculosis Molecular Epidemiology. Journal of Clinical Microbiology, 2016, 54, 478-482.	3.9	6
226	Evaluation of Mycobacterium tuberculosis viability in OMNIgene-SPUTUM reagent upon multi-day transport at ambient temperature. BMC Infectious Diseases, 2017, 17, 663.	2.9	6
227	Multicenter evaluation of xpert MTB/RIF ultra tests reporting detection of â€œTraceâ€•of Mycobacterium tuberculosis DNA. International Journal of Mycobacteriology, 2021, 10, 101.	0.6	6
228	Chitinase-3-like protein-1 at hospital admission predicts COVID-19 outcome: a prospective cohort study. Scientific Reports, 2022, 12, 7606.	3.3	6
229	Meticillin-resistant Staphylococcus aureus SCCmec type IV: nosocomial transmission and colonisation of healthcare workers in a neonatal intensive care unit. Journal of Hospital Infection, 2008, 69, 304-306.	2.9	5
230	Delamanid susceptibility testing ofMycobacterium tuberculosisusing the resazurin microtitre assay and the BACTECâ„¢ MGITâ„¢ 960 systemâ€”authors' response. Journal of Antimicrobial Chemotherapy, 2016, 71, 3625-3625.	3.0	5
231	Bedaquiline Phenotypic and Genotypic Susceptibility Testing, Work in Progress!. EBioMedicine, 2018, 29, 11-12.	6.1	5
232	Latent tuberculous infection among foreign-born individuals applying to shelters in the metropolitan area of Milan. International Journal of Tuberculosis and Lung Disease, 2018, 22, 1160-1165.	1.2	5
233	Tuberculosis Surveillance and Control, Puerto Rico, 1898â€“2015. Emerging Infectious Diseases, 2019, 25, 538-546.	4.3	5
234	Is the new WHO definition of extensively drug-resistant tuberculosis easy to apply in practice?. European Respiratory Journal, 2021, 58, 2100959.	6.7	5

#	Article	IF	Citations
235	Mozambiqueâ€™s journey toward accreditation of the National Tuberculosis Reference Laboratory. African Journal of Laboratory Medicine, 2017, 6, 491.	0.6	5
236	Rapid SARS-CoV-2 Intra-Host and Within-Household Emergence of Novel Haplotypes. Viruses, 2022, 14, 399.	3.3	5
237	Xpert MTB/RIF test for tuberculosis. Lancet, The, 2011, 378, 481-482.	13.7	4
238	Whole-Genome Sequences of Two NDM-1-Producing Pseudomonas aeruginosa Strains Isolated in a Clinical Setting in Albania in 2018. Microbiology Resource Announcements, 2020, 9, .	0.6	4
239	Microbiology of Mycobacterium tuberculosis and a new diagnostic test for TB. , 2012, , 1-13.		4
240	Utility of the Whole Genome Sequencing based methodologies in routine European tuberculosis reference laboratory network setting. Tuberculosis, 2022, 134, 102185.	1.9	4
241	Epidemiological characteristics ofPseudomonas aeruginosa strains causing infection in an Italian general hospital. European Journal of Epidemiology, 1995, 11, 339-344.	5.7	3
242	Mycobacterium sherrisiiPulmonary Disease, Burkina Faso. Emerging Infectious Diseases, 2015, 21, 2093-2094.	4.3	3
243	Long-lasting tuberculous pleurisy. European Respiratory Journal, 2017, 49, 1700356.	6.7	3
244	Implementing TB control in a rural, resource-limited setting: the stop-TB Italia project in Senegal. Multidisciplinary Respiratory Medicine, 2018, 13, 41.	1.5	3
245	A case report of mucocutaneous tuberculosis after orthotopic liver transplantation: a challenging diagnosis. BMC Infectious Diseases, 2018, 18, 431.	2.9	3
246	Lack of association of novel mutation Asp397Gly in aftB gene with ethambutol resistance in clinical isolates of Mycobacterium tuberculosis. Tuberculosis, 2019, 115, 49-55.	1.9	3
247	Tackling TB in migrants arriving at Europeâ€™s southern border. International Journal of Infectious Diseases, 2021, , .	3.3	3
248	Anti-tuberculosis drug resistance in Slovakia, 2018â€“2019: The first whole-genome epidemiological study. Journal of Clinical Tuberculosis and Other Mycobacterial Diseases, 2022, 26, 100292.	1.3	3
249	Screening of migrants for tuberculosis identifies patients with multidrug-resistant tuberculosis but is not sufficient. Clinical Microbiology and Infection, 2018, 24, 918-919.	6.0	2
250	ASAP-GxNet project in Burkina Faso: fulfil country capacity gaps to ensure efficient utilisation of GeneXpert instruments in tuberculosis care and cascade. ERJ Open Research, 2019, 5, 00150-2018.	2.6	2
251	Performance of the GenoType MTBDRsl V 2.0 for detecting second-line drugs resistance of Mycobacterium tuberculosis isolates in Tunisia. Research in Microbiology, 2021, 172, 103816.	2.1	2
252	Saliva molecular testing for SARS-CoV-2: simplifying the diagnosis without losing accuracy. European Respiratory Journal, 2021, 58, 2102099.	6.7	2

#	Article	IF	Citations
253	Equivalence of the GeneXpert System and GeneXpert Omni System for tuberculosis and rifampicin resistance detection. PLoS ONE, 2021, 16, e0261442.	2.5	2
254	Molecular Diagnosis of Rifampin-Monoresistant Tuberculosis in Indian Patients: Problems with a Discordance Analysis. Journal of Clinical Microbiology, 2014, 52, 3503-3503.	3.9	1
255	Unusual Mycobacterial Interspersed Repetitive-Unit Alleles in Loci 580 and 4348 among Mycobacterium tuberculosis Isolates in Albania. Journal of Clinical Microbiology, 2014, 52, 4437-4438.	3.9	1
256	Treating Primary Arthroprosthesis Infection Caused byMycobacterium abscessussubsp. abscessus. Case Reports in Infectious Diseases, 2019, 2019, 1-7.	0.5	1
257	Outbreak of pre- and extensively drug-resistant tuberculosis in northern Italy: urgency of cross-border, multidimensional, surveillance systems. European Respiratory Journal, 2021, 58, 2100839.	6.7	1
258	Applying a Standardized Approach to Strengthen Performances of GeneXpert Networks programme: lessons learned from Burkina Faso, 2019. ERJ Open Research, 2020, 6, 00283-2020.	2.6	1
259	Laboratory diagnosis of tuberculosis. , 0, , 99-115.		1
260	Whole genome sequencing of isoniazid monoresistant clinical isolates of Mycobacterium tuberculosis reveals novel genetic polymorphisms. Tuberculosis, 2022, 133, 102173.	1.9	1
261	Deregulation of the tyrosine kinase associated with the bombesin receptor in small cell lung carcinomas. European Journal of Cancer & Clinical Oncology, 1987, 23, 1752.	0.7	0
262	Proteins phosphorylated on tyrosine as markers of human malignancies. European Journal of Cancer & Clinical Oncology, 1987, 23, 1744-1745.	0.7	0
263	Identification of the Bombesin Receptor on Murine and Human Cells by Cross-Linking Experiments. Annals of the New York Academy of Sciences, 1988, 547, 474-476.	3.8	0
264	Accelerating tuberculosis elimination in low-incidence settings: the role of genomics. European Respiratory Journal, 2015, 46, 1841-1843.	6.7	0
265	The role of entry-screening procedures in the identification of multidrug-resistant Mycobacterium tuberculosis cluster cases amongst patients arriving in Europe from the horn of Africa, 2016-17. International Journal of Infectious Diseases, 2019, 79, 22.	3.3	0
266	Intermittent regimens for tuberculosis treatment: Back to the Future?. European Respiratory Journal, 2020, 56, 2002510.	6.7	0
267	Microbiological Diagnosis of Tuberculosis Disease. , 2021, , 87-96.		0
268	Is deployement of diagnostic test alone enough? Comprehensive package of interventions to strengthen TB laboratory network: three years of experience in Burkina Faso. BMC Infectious Diseases, 2021, 21, 346.	2.9	0
269	Tuberculosis treatment outcomes in a rural area of Senegal: a decade of experience from 2010 to 2019 by StopTB Italia. Future Microbiology, 2021, 16, 399-407.	2.0	0
270	Modeling polymicrobial infections in the pathogenesis of respiratory diseases. , 2017, , .		0

#	Article	IF	Citations
271	Provision of systematic testing for active TB in refugees at CPSA centers. , 2017, , .		0
272	Modulation of QuantiFERON-TB-Gold Plus response in patients with active tuberculosis and latent infection during treatment. , 2017, , .		0
273	Characterization of murine model of chronic M. abscessus respiratory infection.. , 2018, , .		0
274	Draft Genome Sequences of 77 Endemic Multidrug-Resistant Mycobacterium tuberculosis Strains of SIT41 (TUR) Spoligotype from Bulgaria. Microbiology Resource Announcements, 2022, , e0111121.	0.6	0
275	Evaluation of chromogenic medium (ORSAB) for routine identification of methicillin resistant Staphylococcus aureus (MRSA). New Microbiologica, 2005, 28, 83-7.	0.1	0
276	Fragmentation of Healthcare Services as a Possible Determinant of the Low Completion for the Tuberculosis Cascade of Prevention among Asylum Seekers: Results from a Prospective Study with Historical Comparison. Pathogens, 2022, 11, 613.	2.8	0